Instituut voor Neuropathische Pijn
English articles KRN5500 and Neuropathic Pain: weak effect?
| KRN5500 and Neuropathic Pain: weak effect? |
|
KRN5500 is a novel non-opioid analgesic agent, a semi-synthetic derivative of spicamycin: (6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-ß-L-manno-heptopyranosyl]amino-9H-purine). Recently favorable clinical results of a Phase 2 study were reported for the primary endpoint and statistical significance was found for KRN5500 compared to placebo in a blinded, randomized, placebo controlled, dose escalation study in patients with advanced cancer and neuropathic pain.
In a press release of 20 april they stated: "Correlation of Numeric Rating Scale (NRS), Neuropathic Pain Questionnaire (NPQ), and Keywords in Study for Treating Neuropathic Pain with KRN5500." The poster presentation art Athens Dara provide an overview of keywords used by patients in describing their neuropathic pain and the correlation between post-treatment NRS scores and NPQ symptom scores. Baseline correlation was significant for electric (r=0.50), "sensitive to touch" (r=0.58), shooting (r=0.56) and tingling (r=0.55). However, NPQ symptom scores did not correlate post-treatment with the statistically significant improvement seen in the NRS pain scores (combined symptoms). The largest median decrease in NRS scores in patients treated with KRN5500 was 29.3% while the median decrease for patients treated with placebo was zero. No placebo effect and less then 30% response makes the data rather weak we think. DARA BioSciences, Inc. developed KRn 5500 is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules. KRN 5500 is a derivative of an antibiotic, spicamycin, which was serendipious found to be active as an analgesic for neuropathic pain. [1] [2] The compound KRN5500 is also expected to be useful for treatment of refractory cancers due to its antitumor mechanism. [3] March 2010, Jan M. Keppel Hesselink, MD, PhD Referenties[1]: Borsook D, Edwards AD. | Antineuropathic effects of the antibiotic derivative spicamycin KRN5500. | Pain Med. | 2004 Mar;5(1):104-8. [2]: Abdi S, Vilassova N, Decosterd I, Feroz N, Borsook D. | The effects of KRN5500, a spicamycin derivative, on neuropathic and nociceptive pain models in rats. | Anesth Analg. | 2000 Oct;91(4):955-9. |